02/01/23 8:00 AMNasdaq : OCGN managementhigh shortOcugen Appoints Quan A. Vu as Chief Business OfficerOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer,RHEA-AIneutral
01/31/23 8:00 AMNasdaq : OCGN conferenceshigh shortOcugen, Inc. to Present at 2023 BIO CEO & Investor ConferenceOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief ExecutiveRHEA-AIneutral
01/09/23 6:00 AMNasdaq : OCGN clinical trialcovid-19high shortOcugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints MetStudy met both co-primary endpoints with robust immune responses COVAXIN ™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the United States (U.S.), with no vaccine-related serious adverse events, thrombotic events, or casesRHEA-AInegative
12/16/22 6:30 AMNasdaq : OCGN clinical trialhigh shortOcugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, andRHEA-AIpositive
12/15/22 5:15 PMNasdaq : OCGN high shortOcugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital AmaurosisOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializingRHEA-AIvery positive
12/13/22 8:00 AMNasdaq : OCGN high shortOcugen, Inc. to Ring the Nasdaq Stock Market Closing BellOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief ExecutiveRHEA-AIneutral
12/07/22 8:00 AMNasdaq : OCGN clinical trialhigh shortOcugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital AmaurosisOcugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, andRHEA-AIneutral
11/28/22 7:30 AMNasdaq : OCGN conferenceshigh shortOcugen to Present at 3rd Annual Dry AMD Therapeutics SummitOcugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’s Chief Scientific Officer, ArunRHEA-AIneutral
11/08/22 7:30 AMNasdaq : OCGN earningshigh shortOcugen Provides Business Update & Third Quarter 2022 Financial ResultsConference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in the third and final cohort of U.S. Phase 1/2 OCU400 gene therapy clinical trial Expanded product pipeline with OCU500—Ocugen’s mucosal COVID-19 vaccine and OCU410ST for Stargardt disease Completed enrollment of U.S. Phase 2/3RHEA-AIneutral
10/27/22 7:30 AMNasdaq : OCGN conferencesearningshigh shortOcugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial ResultsOcugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcastRHEA-AIneutral